Core Viewpoint - The company announced that the post-hoc analysis of the early efficacy of CU-10201 for treating moderate to severe acne vulgaris has been selected for oral presentation at the 20th CDA Annual Meeting, highlighting the significance of this treatment option in the dermatology field [1] Group 1: Product Information - CU-10201 is the first and only approved topical minocycline for the treatment of acne vulgaris globally, and it has received priority review and approval from the National Medical Products Administration of China [1] - The efficacy and safety of CU-10201 for moderate to severe acne vulgaris patients in China have been confirmed through a Phase III clinical trial [1] Group 2: Clinical Findings - The post-hoc analysis aimed to evaluate the early efficacy of CU-10201 in patients with moderate to severe facial acne vulgaris during the first and second weeks of treatment [1] - The analysis showed that CU-10201 demonstrated significant rapid efficacy, with noticeable improvement in inflammatory lesions observed in the first week and further enhancement of efficacy by the second week [1] - These early efficacy data indicate that CU-10201 can provide a rapid symptom relief treatment option for acne vulgaris patients, which holds important clinical significance [1]
科笛-B(02487.HK)：CU-10201(外用4%米诺环素泡沫剂)一项中国III期临床试验的事后分析被选为在第二十届CDA年会口头发言